Trial Profile
A Phase III Trial to Evaluate Once-Monthly (Once Every Four Weeks) Intramuscular Route of Administration of Ibalizumab
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 19 Jul 2022
Price :
$35
*
At a glance
- Drugs Ibalizumab (Primary)
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Sponsors Theratechnologies
- 19 May 2021 According to a TaiMed Biologics media release, company made the agreement with Theratechnologies Inc. to initiate this study. Related costs and expenses will be paid by Theratechnologies Inc. and no effect on the profit sharing of the marketing agreement.
- 19 May 2021 Status changed from planning to recruiting, according to a TaiMed Biologics media release.
- 14 Apr 2021 According to a Theratechnologies media release, Theratechnologies and TaiMed are planning to evaluate an intramuscular (IM) method of administration for Trogarzo and the study will be conducted and funded by Theratechnologies.